This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pierson-Mullany, L. K. Articles by Lange, C. A. Search for Related Content PubMed PubMed Citation Articles by Pierson-Mullany, L. K. Articles by Lange, C. A.

Phosphorylation of Progesterone Receptor Serine 400 Mediates Ligand-Independent Transcriptional Activity in Response to Activation of Cyclin-Dependent Protein Kinase 2

Department of Pharmacology,¹ Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota Cancer Center, University of Minnesota, Minneapolis, Minnesota²

Received 20 August 2004/ Returned for modification 16 September 2004/ Accepted 20 September 2004

Human progesterone receptors (PR) are phosphorylated by cyclin-dependent protein kinase 2 (CDK2) at multiple sites, including Ser400. Herein, we have addressed the significance of phosphorylation of this residue. PR phospho-Ser400-specific antibodies revealed regulated phosphorylation of Ser400 in response to progestins and mitogens, and this correlated with increased CDK2 levels and activity. Expression of cyclin E elevated CDK2 activity and downregulated PR independently of ligand. Similarly, overexpression of activated mutant CDK2 increased PR transcriptional activity in the absence and presence of progestin. Mutation of PR Ser400 to alanine (S400A) blocked CDK2-induced PR activity in the absence, but not in the presence, of progestin. PR was unresponsive to activated CDK2 in breast cancer cells with elevated p27, and RNA interference knock-down of p27 partially restored CDK2-induced ligand-independent PR activation. Similarly, in p27^–/– mouse embryonic fibroblasts, elevated CDK2 activity increased wild-type (wt) but not S400A PR transcriptional activity in the absence of progestin. CDK2 induced nuclear localization of unliganded wt but not S400A PR; liganded S400A PR exhibited delayed nuclear accumulation. These studies demonstrate that CDK2 regulates PR in the absence of progestins via phosphorylation of Ser400, thus revealing a novel mechanism for upregulated PR transcriptional activity in human breast cancer cells expressing altered cell cycle regulatory molecules.

This article has been cited by other articles:

• Arpino, G., Wiechmann, L., Osborne, C. K., Schiff, R. (2008). Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance. Endocr. Rev. 29: 217-233 [Abstract] [Full Text]  
• Daniel, A. R., Faivre, E. J., Lange, C. A. (2007). Phosphorylation-Dependent Antagonism of Sumoylation Derepresses Progesterone Receptor Action in Breast Cancer Cells. Mol. Endocrinol. 21: 2890-2906 [Abstract] [Full Text]  
• McCarthy, T. L., Hochberg, R. B., Labaree, D. C., Centrella, M. (2007). 3-Ketosteroid Reductase Activity and Expression by Fetal Rat Osteoblasts. J. Biol. Chem. 282: 34003-34012 [Abstract] [Full Text]  
• Weigel, N. L., Moore, N. L. (2007). Steroid Receptor Phosphorylation: A Key Modulator of Multiple Receptor Functions. Mol. Endocrinol. 21: 2311-2319 [Abstract] [Full Text]  
• Romano, A., Delvoux, B., Fischer, D.-C., Groothuis, P. (2007). The PROGINS polymorphism of the human progesterone receptor diminishes the response to progesterone. J Mol Endocrinol 38: 331-350 [Abstract] [Full Text]  
• Faivre, E. J., Lange, C. A. (2007). Progesterone Receptors Upregulate Wnt-1 To Induce Epidermal Growth Factor Receptor Transactivation and c-Src-Dependent Sustained Activation of Erk1/2 Mitogen-Activated Protein Kinase in Breast Cancer Cells. Mol. Cell. Biol. 27: 466-480 [Abstract] [Full Text]  
• An, B.-S., Selva, D. M., Hammond, G. L., Rivero-Muller, A., Rahman, N., Leung, P. C. K. (2006). Steroid Receptor Coactivator-3 Is Required for Progesterone Receptor Trans-activation of Target Genes in Response to Gonadotropin-releasing Hormone Treatment of Pituitary Cells. J. Biol. Chem. 281: 20817-20824 [Abstract] [Full Text]